<!DOCTYPE html>
<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/
-->
<!--[if lt IE 7]>
<html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en">
<![endif]-->
<!--[if IE 7]>
<html class="no-js lt-ie9 lt-ie8" lang="en">
<![endif]-->
<!--[if IE 8]>
<html class="no-js lt-ie9" lang="en">
<![endif]-->
<!--[if gt IE 8]>
<!-->
<html class="no-js" lang="en">
<!--<![endif]-->

<head>
    <meta charset="utf-8" />
    <!-- Set the viewport width to device width for mobile -->
    <meta name="viewport" content="width=device-width" />
    <title>
        PracticeUpdate : Expert Opinion Item
    </title>
    <link rel="stylesheet" href="assets/css/app.css">
    <link rel="stylesheet" href="assets/css/font-awesome.css">
    <link rel="stylesheet" href="assets/css/fc-webicons.css">
    <link rel="stylesheet" href="assets/css/foundation-icons-general.css">
    <script src="assets/js/foundation/modernizr.foundation.js">
    </script>
    <!-- IE Fix for HTML5 Tags -->
    <!--[if lt IE 9]>
        <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js">
        </script>
    <![endif]-->
</head>

<body id="page" class="update off-canvas slide-nav expert-opinion-item logged-out">
    <div class="widget ad">
        <div id="leaderboard" class="Breast ad-container">
            <div class="ad-title">
                <span class="ad-title-text">
                    advertisement
                </span>
            </div>
            <!--/.ad-title-->
            <div id="leaderboardcontent" class="ad-content">
            </div>
            <!--.ad-content-->
        </div>
        <!--/#leaderboard.ad-container-->
    </div>
    <!--/.widget.ad-->
    <div class="page-header">
    </div>
    <!--/.page-header-->
    <div class="page-content">
        <section role="main">
            <div class="single-item-container">
                <article class="type-expert-opinion single-item">
                    <!-- info taken from: http://oncologystat.com/viewpoints/seminal_articles/Seminal_Articles_Germ_Cell_Tumors.html
                    -->
                    <div class="item-header-container">
                        <header class="item-header">
                            <div class="flag-container">
                                <span class="flag featured">
                                    <i class="icon-bolt">
                                    </i>
                                    featured
                                </span>
                                <span class="flag story-of-the-week">
                                    <i class="icon-bolt">
                                    </i>
                                    story of the week
                                </span>
                            </div>
                            <div class="meta pub-meta">
                                <span class="item-type">
                                    Seminal Article
                                </span>
                                <span class="item-pub-date">
                                    <time datetime="12-12-19">
                                        December 19, 2012
                                </span>
                            </div>
                            <hgroup class="item-title-container">
                                <h1 class="item-title">
                                    Seminal Articles—Colorectal Cancer
                                </h1>
                                <p class="item-citation">
                                    <!-- {{source.citation}} -->
                                    2012 Dec 11, Axel Grothey, MD
                                </p>
                            </hgroup>
                            <!-- /.item-title-container -->
                        </header>
                    </div>
                    <!--/.item-header-container-->
                    <div class="item-content-container">
                        <div class="item-content">
                            <div class="item-content-section">
                                <section class="seminal-article-body">
                                    <div class="seminal-article-body-container">
                                        <div class="source-container">
                                            <div class="vcard">
                                            </div>
                                            <!--/.vcard-->
                                        </div>
                                        <!--/.source-container-->
                                        <p>Based on our expert's review, here are the must-read articles for every oncologist about patients with colorectal cancer.</p><p><strong>Prevention and Risk Factors of Colorectal Cancers</strong></p><p>1. Park Y, Hunter DJ, Spiegelman D, et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. <a target="_blank" href="http://jama.ama-assn.org/content/294/22/2849.full">JAMA. 2005;294(22):2849-2857</a>. <strong>Free</strong></p><p>2. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. <a target="_blank" href="http://jco.ascopubs.org/content/24/22/3535.long">J Clin Oncol. 2006;24(22):3535-3541</a>.</p><p>3. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. <a target="_blank" href="http://jco.ascopubs.org/content/26/25/4109.full">J Clin Oncol. 2008;26(25):4109-4115</a>.</p><p>4. Flossmann E, Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. <a target="_blank" href="http://www.sciencedirect.com/science/article/pii/S0140673607607478">Lancet. 2007;369(9573):1603-1613</a>.</p><p>5. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa021633">N Engl J Med. 2003;348(10):883-890</a>. <strong>Free</strong></p><p>6. Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa0801297">N Engl J Med. 2008;359(24):2567-2578</a>. <strong>Free</strong></p><p><strong>Hereditary Colon Cancer</strong></p><p>7. De Jong AE, Morreau H, Van Puijenbroek M, et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. <a target="_blank" href="http://www.sciencedirect.com/science/article/pii/S0016508503017116">Gastroenterology. 2004;126(1):42-48</a>.</p><p>8. Vasen HF, Möslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740877/">J Med Genet. 2007;44(6):353-362</a>. <strong>Free</strong></p><p><strong>Screening for Colon Cancer</strong></p><p>9. Kim DH, Pickhardt PJ, Taylor AJ, et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa070543">N Engl J Med. 2007;357(14):1403-1412</a>. <strong>Free</strong></p><p>10. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. <a target="_blank" href="http://onlinelibrary.wiley.com/doi/10.3322/CA.2007.0018/pdf">CA Cancer J Clin. 2008;58(3):130-160</a>. <strong>Free</strong></p><p><strong>Surgery for Colon Cancer</strong></p><p>11. The Clinical Outcomes of Surgical Therapy Study Group: A comparison of laparoscopically assisted and open colectomy for colon cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa032651">N Engl J Med. 2004;350(20):2050-2059</a>. <strong>Free</strong></p><p><strong>Prognostic or Predictive Factors in Colon Cancer</strong></p><p>12. O'Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940392/">J Clin Oncol. 2010;28(25):3937-3944</a>. <strong>Free</strong></p><p>13. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. <a target="_blank" href="http://www.nejm.org/doi/pdf/10.1056/NEJMoa022289">N Engl J Med. 2003;349(3)247-257</a>. <strong>Free</strong></p><p>14. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903323/">J Clin Oncol. 2010;28(20):3219-3226</a>. <strong>Free</strong></p><p>15. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. <a target="_blank" href="http://jco.ascopubs.org/content/23/34/8664.long">J Clin Oncol. 2005;23(34):8664-8670</a>.</p><p>16. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. <a target="_blank" href="http://jco.ascopubs.org/content/29/1/17.long">J Clin Oncol. 2011;29(1):17-24</a>.</p><p><strong>Adjuvant Therapy in Colon Cancer</strong></p><p>17. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJM199002083220602">N Engl J Med. 1990;322(6):352-358</a>. <strong>Free</strong></p><p>18. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. <a target="_blank" href="http://jco.ascopubs.org/content/17/5/1356.long">J Clin Oncol. 1999;17(5):1356-1363</a>.</p><p>19. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa043116">N Engl J Med. 2005;352(6):2696-2704</a>. <strong>Free</strong></p><p>20. Quasar Collaborative G, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. <a target="_blank" href="http://www.sciencedirect.com/science/article/pii/S0140673607618662">Lancet. 2007;370(9604):2020-2029</a>.</p><p>21. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa032709">N Engl J Med. 2004;350(23):2343-2351</a>. <strong>Free</strong></p><p>22. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. <a target="_blank" href="http://jco.ascopubs.org/content/27/19/3109.long">J Clin Oncol. 2009;27(19):3109-3116</a>.</p><p>23. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188282/">J Clin Oncol. 29(28):3768-3774</a>. <strong>Free</strong></p><p>24. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. <a target="_blank" href="http://jco.ascopubs.org/content/29/11/1465.long">J Clin Oncol. 2011;29(11):1465-1471</a>.</p><p>25. Grothey A. Risk assessment in stage II colon cancer: to treat or not to treat? <a target="_blank" href="http://www.cancernetwork.com/colorectal-cancer/content/article/10165/1513497">Oncology (Williston Park). 2012;24(Suppl 1):1-2</a>.</p><p><strong>Adjuvant Therapy in Elderly</strong></p><p>26. Sanoff HK, Carpenter WR, Til Stürmer T, et al. Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years. <a target="_blank" href="http://jco.ascopubs.org/content/30/21/2624.abstract">J Clin Oncol. 2012;30(21):2624-2634</a>.</p><p><strong>Biologics in Adjuvant Therapy</strong></p><p>27. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055856/">J Clin Oncol. 2011;29(1):11-16</a>.</p><p>28. Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. Paper presented at: American Society of Clinical Oncology Annual Meeting; 2010; Chicago, IL. <a target="_blank" href="http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=41265">Abstract CRA3507</a>.</p><p><strong>Chemotherapy for Metastatic Disease</strong></p><p>29. Grothey A, Marshall JL: Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy. <a target="_blank" href="http://www.cancernetwork.com/display/article/10165/61558">Oncology (Williston Park). 2007;21(5):553-564</a>.</p><p>30. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. <a target="_blank" href="http://jco.ascopubs.org/content/19/8/2282.long">J Clin Oncol. 2001;19(8):2282-2292</a>.</p><p>31. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. <a target="_blank" href="http://jco.ascopubs.org/content/26/12/2006.full">J Clin Oncol. 2008;26(12):2006-2012</a>.</p><p>32. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. <a target="_blank" href="http://www.sciencedirect.com/science/article/pii/S0140673600020341">Lancet. 2000;355(9209):1041-1047</a>.</p><p>33. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJM200009283431302">N Engl J Med. 2000;343(13):905-914</a>. <strong>Free</strong></p><p>34. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. <a target="_blank" href="http://www.sciencedirect.com/science/article/pii/S0140673607610873">Lancet. 2007;370(99582):143-152</a>.</p><p>35. Köhne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. <a target="_blank" href="http://jco.ascopubs.org/content/23/22/4856.full">J Clin Oncol. 2005;23(2):4856-4865</a>.</p><p>36. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. <a target="_blank" href="http://jco.ascopubs.org/content/18/16/2938.full">J Clin Oncol. 2000;18(16):2938-2947</a>.</p><p>37. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. <a target="_blank" href="http://jco.ascopubs.org/content/21/11/2059.full">J Clin Oncol. 2003;21(11):2059-2069</a>.</p><p>38. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. <a target="_blank" href="http://jco.ascopubs.org/content/22/1/23.full">J Clin Oncol. 2004;22(1):23-30</a>.</p><p>39. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. <a target="_blank" href="http://jco.ascopubs.org/content/22/2/229.long">J Clin Oncol. 2004;22(2):229-237</a>.</p><p>40. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. <a target="_blank" href="http://jco.ascopubs.org/content/22/7/1209.long">J Clin Oncol. 2004;22(7):1209-1214</a>.</p><p>41. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. <a target="_blank" href="http://jco.ascopubs.org/content/25/13/1670.full">J Clin Oncol. 2007;25(13):1670-1676</a>.</p><p><strong>Biologics in Metastatic Disease</strong></p><p>42. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa032691">N Engl J Med. 2004;350(23):2335-2342</a>. <strong>Free</strong></p><p>43. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. <a target="_blank" href="http://jco.ascopubs.org/content/25/12/1539.full">J Clin Oncol. 2007;25 (12):1539-1544</a>.</p><p>44. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. <a target="_blank" href="http://jco.ascopubs.org/content/23/16/3706.long">J Clin Oncol. 2005;23(16):3706-3712</a>.</p><p>45. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. <a target="_blank" href="http://jco.ascopubs.org/content/26/12/2013.full">J Clin Oncol. 2008;26(12):2013-2019</a>.</p><p>46. Hecht JR, Mitchell E, Chidiac T, et al. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. <a target="_blank" href="http://jco.ascopubs.org/content/27/5/672.long">J Clin Oncol. 2008;27(5):672-680</a>.</p><p>47. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. <a target="_blalnk" href="http://www.nejm.org/doi/full/10.1056/NEJMoa0808268">N Engl J Med. 2009;360(5):563-572</a>. <strong>Free</strong></p><p>48. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa033025">N Engl J Med. 2004;351(4):337-345</a>. <strong>Free</strong></p><p>49. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. <a target="_blank" href="http://jco.ascopubs.org/content/25/13/1658.full">J Clin Oncol. 2007;25(13):1658-1664</a>.</p><p>50. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa071834">N Engl J Med. 2007;357(20):2040-2048</a>. <strong>Free</strong></p><p>51. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. <a target="_blank" href="http://jco.ascopubs.org/content/28/31/4697.long">J Clin Oncol. 2010;28(31):4697-4705</a>.</p><p>52. Van Cutsem E, Köhne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. <a target="_blank" href="http://jco.ascopubs.org/content/29/15/2011.long">J Clin Oncol. 2011;29(15):2011-2019</a>.</p><p>53. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa0805019">N Engl J Med. 2009;360(14):1408-1417</a>. <strong>Free</strong></p><p>54. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa0804385">N Engl J Med. 2008;359(17):1757-1765</a>.</p><p>55. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. <a target="_blank" href="http://cancerres.aacrjournals.org/content/66/8/3992.full">Cancer Res. 2006:66(8):3992-3995</a>. <strong>Free</strong></p><p>56. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159415/">Lancet. 2011;377(9783):2103-2114</a>. <strong>Free</strong></p><p>57. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. <a target="_blank" href="http://jco.ascopubs.org/content/30/28/3499.abstract">J Clin Oncol. 2012;30(28):3499-3506</a>.</p><p>58. Grothey A, Sobrero AF, Siena S, et al. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.Paper presented at: American Society of Clinical Oncology Annual Meeting; 2012; Chicago, IL. LBA385. Has now been published in <a target="_blank" href="http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=115&amp;abstractID=87795">Lancet</a></p><p><strong>Toxicities</strong></p><p>59. Grothey A. Oxaliplatin-safety profile: neurotoxicity. <a target="_blank" href="http://www.sciencedirect.com/science/article/pii/S0093775403003993">Semin Oncol. 2003;30(Suppl 15):5-13</a>.</p><p>60. Grothey A. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. <a target="_blank" href="http://www.cancernetwork.com/display/article/10165/60418">Oncology (Williston Park). 2006;20(14 Suppl 10):21-28</a>.</p><p>61. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. <a target="_blank" href="http://jama.ama-assn.org/content/300/19/2277.longn">JAMA. 2008;300(19):2277-2285</a>. <strong>Free</strong></p><p>62. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa074943">N Engl J Med. 2008;358(11):1109-1117</a>. <strong>Free</strong></p><p>63. Lacouture ME, Anadkat MJ, Bensadoun R-J, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128700/">Support Care Cancer. 2011;19(8):1079-11095</a>. <strong>Free</strong></p><p><strong>Curative Intent in Stage IV Disease</strong></p><p>64. Poston GJ, Adam R, Alberts S, et al. OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal Cancer. <a target="_blank" href="http://jco.ascopubs.org/content/23/28/7125.full">J Clin Oncol. 2005;23(28):7125-7134</a>.</p><p>65. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1420876/?tool=pubmed">Ann Surg. 1999;230(3):309-318</a>. <strong>Free</strong></p><p>66. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2277487/">Lancet. 2008;371(9617):1007-1016.</a><strong>Free</strong></p><p>67. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. <a target="_blank" href="http://annonc.oxfordjournals.org/content/16/8/1311.long">Ann Oncol. 2005;16(8):1311-1319</a>. <strong>Free</strong></p><p>68. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. <a target="_blank" href="http://jco.ascopubs.org/content/26/30/4906.full">J Clin Oncol. 2008;26(30):4906-4911</a>.</p><p><strong>Rectal Cancer</strong></p><p>69. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668947/">Lancet. 2009;373(9666):811-820</a>. <strong>Free</strong></p><p>70. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. <a target="_blank" href="http://www.sciencedirect.com/science/article/pii/S0140673686915102">Lancet. 1986;1(8496):1479-1482</a>.</p><p>71. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa010580">N Engl J Med. 2001;345(9):638-646</a>. <strong>Free</strong></p><p>72. Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668948/">Lancet. 2009;373(9666):821-828</a>. <strong>Free</strong></p><p>73. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa040694">N Engl J Med. 2004;351(17):1731-1740</a>. <strong>Free</strong></p><p>74. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJM199704033361402">N Engl J Med. 1997;336(14):980-987</a>.</p><p>75. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJM199103143241101">N Engl J Med. 1991;324(11):709-715</a>. <strong>Free</strong></p><p>76. Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. <a target="_blank" href="http://jnci.oxfordjournals.org/content/80/1/21.abstract">J Natl Cancer Inst. 1988;80(1):21-29</a>.</p><p>77. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJM199408253310803">N Engl J Med. 1994;331(8):502-507</a>. <strong>Free</strong></p><p>78. Roh MS, Yothers GA, O'Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. Paper presented at: American Society of Clinical Oncology Annual Meeting; 2011; Chicago, IL. <a target="_blank" href="http://www.asco.org/ascov2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=76910">Abstract 3503</a>.</p><p>79. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. <a target="_blank" href="http://jco.ascopubs.org/content/29/20/2773.long">J Clin Oncol. 2011;29(20):2773-2780</a>.</p><p>80. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. <a target="_blank" href="http://jco.ascopubs.org/content/28/10/1638.full">J Clin Oncol. 2011;28(10):1638-1644</a>.</p><p>81. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. <a target="_blank" href="http://onlinelibrary.wiley.com/doi/10.1002/bjs.5506/full">Br J Surg. 2006;93(10):1215-1223</a>.</p><p>82. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. <a target="_blank" href="http://jco.ascopubs.org/content/30/16/1926.abstract">J Clin Oncol. 2012;30(16):1926-1933</a>.</p><p></p>
                                    </div>
                                    <!--/.seminal-article-body-container -->
                                </section>
                                <!-- /.seminal-article-body -->
                            </div>
                            <!-- ./item-content-section -->
                        </div>
                        <!-- ./item-content -->
                    </div>
                    <!-- /.item-conten-container -->
                    <hr />
                    <footer class="copyright item-footer">
                        <img class="logo" src="content/img/feed/imng_logo.gif" alt="IMNG Medical Media"
                        />
                        <p>
                            Copyright &copy; 2012 Elsevier
                        </p>
                    </footer>
            </div>
            <!--/.item-container-->
            <div class="recommended">
                <div class="recent">
                </div>
                <!--/.recent-->
                <div class="ad">
                    <img src="http://placehold.it/300x250" align="ad" title="ad" />
                </div>
            </div>
            <!--/.recommended-->
        </section>
        <!--/[role="main"]-->
        <section id="sidebar" role="complementary">
            <div class="dashboard">
                <div class="panel cta register">
                    <p>
                        <!-- Meet Our Experts -->
                        Become a member to customize this page.
                        <p>
                            <a class="button" href="#action-register">Register for free</a>
                </div>
                <!--/.panel.cta.register-->
                <div class="component user-console">
                </div>
                <!--/.component.user-console-->
                <div class="component user-topic">
                </div>
                <!--/.component.user-topic-->
                <div class="component topic-spotlight">
                </div>
                <!--/.component.topic-spotlight-->
                <div class="panel">
                    <img src="http://placehold.it/200x200" />
                    <p>
                        <!-- Meet Our Experts -->
                        Meet our Advisory and Editorial Boards comprised of physician editors
                        and world-renowned experts.
                        <p>
                </div>
            </div>
            <!--/.sidebar-->
        </section>
        <!--/.[role="complimentary"]-->
    </div>
    <!--/.page-content-->
	<div class="page-footer-container">
    <footer class="page-footer">
    </footer>
	</div><!-- /.page-footer-container -->
    <!-- /.page-footer -->
    <!-- Included JS Files (Uncompressed) -->
    <script src="assets/js/foundation/jquery.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.accordion.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.alerts.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.buttons.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.forms.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.mediaQueryToggle.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.navigation.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.orbit.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.reveal.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tabs.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tooltips.js">
    </script>
    <script src="assets/js/foundation/jquery.placeholder.js">
    </script>
    <script src="assets/js/foundation/app.js">
    </script>
    <script src="assets/js/foundation/jquery.offcanvas.js">
    </script>
    <script src="assets/js/mustache.js">
    </script>
    <!-- Mustache - homepage feed template -->
    <script>
                    	<!--
	Mustache - homepage feed template -->
	$.getJSON('content/json/feed.json', function(data) {
	    $.get('assets/mustache/feed-item.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.stream-container').html(html);
	    });

	});

	<!--
	Mustache - homepage recent template -->
	$.getJSON('content/json/recent.json', function(data) {
	    $.get('assets/mustache/recent.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.recent').html(html);
	    });

	});

	<!--
	Mustache - homepage user - console template -->
	$.getJSON('content/json/user-console.json', function(data) {
	    $.get('assets/mustache/user-console.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-console').html(html);
	    });
	});

	<!--
	Mustache - homepage user - topic template -->
	$.getJSON('content/json/user-topic.json', function(data) {
	    $.get('assets/mustache/user-topic.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-topic').html(html);
	    });
	});

	<!--
	Mustache - homepage topic - spotlight template -->
	$.getJSON('content/json/topic-spotlight.json', function(data) {
	    $.get('assets/mustache/topic-spotlight.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.topic-spotlight').html(html);
	    });
	});
</script>
</body>

</html>